Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer

Ads

You May Also Like

Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results

VANCOUVER, British Columbia, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

BeiGene Announces Pricing of $200 Million Public Offering

WALTHAM, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical ...

Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results

PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...